KR101443795B1 - 항균성 조성물 - Google Patents

항균성 조성물 Download PDF

Info

Publication number
KR101443795B1
KR101443795B1 KR1020097001499A KR20097001499A KR101443795B1 KR 101443795 B1 KR101443795 B1 KR 101443795B1 KR 1020097001499 A KR1020097001499 A KR 1020097001499A KR 20097001499 A KR20097001499 A KR 20097001499A KR 101443795 B1 KR101443795 B1 KR 101443795B1
Authority
KR
South Korea
Prior art keywords
pyridin
ethyl
benzothiazol
urea
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001499A
Other languages
English (en)
Korean (ko)
Other versions
KR20090029817A (ko
Inventor
데빗 존 하이던
로이드 죠오지 차플류스키
니콜라스 죤 팔머
달 로버트 미첼
죤 프레더릭 애더올
크리스토퍼 리차드 스틸리
타마라 래두와히티
Original Assignee
바이오타 유럽 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오타 유럽 리미티드 filed Critical 바이오타 유럽 리미티드
Publication of KR20090029817A publication Critical patent/KR20090029817A/ko
Application granted granted Critical
Publication of KR101443795B1 publication Critical patent/KR101443795B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020097001499A 2006-06-22 2007-06-21 항균성 조성물 Expired - Fee Related KR101443795B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612428.3 2006-06-22
GBGB0612428.3A GB0612428D0 (en) 2006-06-22 2006-06-22 Antibacterial agents
PCT/GB2007/002314 WO2007148093A1 (en) 2006-06-22 2007-06-21 Antibacterial compositions

Publications (2)

Publication Number Publication Date
KR20090029817A KR20090029817A (ko) 2009-03-23
KR101443795B1 true KR101443795B1 (ko) 2014-10-21

Family

ID=36803739

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001499A Expired - Fee Related KR101443795B1 (ko) 2006-06-22 2007-06-21 항균성 조성물

Country Status (21)

Country Link
US (2) US7977340B2 (https=)
EP (1) EP2034997B1 (https=)
JP (1) JP5309021B2 (https=)
KR (1) KR101443795B1 (https=)
CN (1) CN101472585B (https=)
AU (1) AU2007262791B2 (https=)
BR (1) BRPI0713501A2 (https=)
CA (1) CA2655403C (https=)
DK (1) DK2034997T3 (https=)
EA (1) EA019748B1 (https=)
ES (1) ES2403005T3 (https=)
GB (1) GB0612428D0 (https=)
IL (1) IL195687A (https=)
MX (1) MX2008015706A (https=)
MY (1) MY148682A (https=)
NZ (1) NZ574313A (https=)
PL (1) PL2034997T3 (https=)
PT (1) PT2034997E (https=)
SG (1) SG172676A1 (https=)
WO (1) WO2007148093A1 (https=)
ZA (1) ZA200900240B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
ATE507225T1 (de) 2006-12-04 2011-05-15 Astrazeneca Ab Antibakterielle polycyclische harnstoffverbindungen
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2277870A1 (de) * 2009-06-24 2011-01-26 Bayer CropScience AG Substituierte Benzoxa(thia)zole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
ES2568455T3 (es) 2010-06-01 2016-04-29 Summit Therapeutics Plc Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2012097270A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
CN103384665B (zh) 2011-01-14 2018-01-09 斯派罗吹耐姆公司 制备促旋酶和拓扑异构酶抑制剂的方法
AU2012205415B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Pyrimidine gyrase and topoisomerase IV inhibitors
US8476281B2 (en) 2011-01-14 2013-07-02 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
CN103702994B (zh) 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
EP2828245A1 (en) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Antimicrobial agents
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US20160194279A1 (en) * 2012-12-09 2016-07-07 Council Of Scientific & Industrial Research One pot process for the conversion of aroyl chlorides to acyl thioureas
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
MX2016010057A (es) 2014-02-03 2017-04-27 Spero Gyrase Inc Compuestos antibacterianos.
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN107207526A (zh) * 2014-12-02 2017-09-26 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
US10513528B2 (en) 2016-02-25 2019-12-24 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
WO2018183917A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
KR102737283B1 (ko) 2019-07-17 2024-12-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법
US20230247994A1 (en) 2020-07-02 2023-08-10 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
EP4398890A4 (en) 2021-09-09 2025-07-30 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Univ Of Nevada Las Ve C. Difficile Spore Germination Inhibitors
CN116444376B (zh) * 2023-04-19 2024-01-26 德兴市德邦化工有限公司 一种3,5-二氯硝基苯的生产工艺
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
CN119350937B (zh) * 2024-10-30 2025-08-12 广东豪之盛新材料有限公司 一种双组份气雾喷漆及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
JP2003521543A (ja) * 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
AU8181701A (en) * 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
TW200621723A (en) * 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof

Also Published As

Publication number Publication date
IL195687A (en) 2013-12-31
US7977340B2 (en) 2011-07-12
MY148682A (en) 2013-05-31
JP2009541289A (ja) 2009-11-26
SG172676A1 (en) 2011-07-28
IL195687A0 (en) 2009-09-01
KR20090029817A (ko) 2009-03-23
MX2008015706A (es) 2009-03-31
DK2034997T3 (da) 2013-02-11
CA2655403C (en) 2014-02-04
GB0612428D0 (en) 2006-08-02
JP5309021B2 (ja) 2013-10-09
US20090197877A1 (en) 2009-08-06
CN101472585B (zh) 2013-12-04
CA2655403A1 (en) 2007-12-27
US20110263590A1 (en) 2011-10-27
CN101472585A (zh) 2009-07-01
PL2034997T3 (pl) 2013-04-30
EA019748B1 (ru) 2014-06-30
AU2007262791A1 (en) 2007-12-27
NZ574313A (en) 2011-10-28
ZA200900240B (en) 2009-12-30
EA200900047A1 (ru) 2009-06-30
US8389516B2 (en) 2013-03-05
PT2034997E (pt) 2013-01-24
EP2034997A1 (en) 2009-03-18
ES2403005T3 (es) 2013-05-13
EP2034997B1 (en) 2012-10-17
AU2007262791B2 (en) 2012-11-08
BRPI0713501A2 (pt) 2012-03-13
WO2007148093A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
KR101443795B1 (ko) 항균성 조성물
CN102015700B (zh) 抗菌稠合噻唑
US9181234B2 (en) Antibacterial compounds
KR20070026318A (ko) 항균 활성을 갖는 피롤 유도체
NZ578159A (en) Antibacterial polycyclic urea compounds
US8481544B2 (en) Antibacterial compositions
CN101005843A (zh) 吡咯并三嗪激酶抑制剂
US8673922B2 (en) Azaindazole compounds
WO1997032854A1 (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
AU2012200669B2 (en) Antibacterial compositions
TW202529756A (zh) 用於預防或治療癌症的新穎雜環化合物和包括其作為DNA聚合酶θ抑制劑的藥物組合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170918

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170918